{
    "clinical_study": {
        "@rank": "158070", 
        "arm_group": [
            {
                "arm_group_label": "L-R-E arm", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 + everolimus + exemestane triple combination"
            }, 
            {
                "arm_group_label": "L-E arm", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 + exemestane double combination"
            }, 
            {
                "arm_group_label": "R-E arm", 
                "arm_group_type": "Active Comparator", 
                "description": "everolimus + exemestane double combination"
            }
        ], 
        "brief_summary": {
            "textblock": "To estimate the MTD(s) and/ or RP2D of LEE011 in combination with everolimus + exemestane,\n      and LEE011 in combination with exemestane, and to characterize the safety and tolerability\n      of the combinations of everolimus + exemestane \u00b1 LEE011 and LEE011 + exemestane in patients\n      with ER+ HER2- advanced breast cancer"
        }, 
        "brief_title": "Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The primary purpose of the phase Ib part of this study is to determine the maximum tolerated\n      dose(s) (MTD(s)) and/or recommended phase II dose (RP2D) of LEE011 + everolimus + exemestane\n      in patients with ER+ Her2- advanced breast cancer. This part of the study will also assess\n      safety, tolerability, and PK of the LEE011 + exemestane, LEE011 + everolimus + exemestane\n      combinations.\n\n      The phase II part of the study will evaluate the triple combination of LEE011 + everolimus +\n      exemestane and the double combination of LEE011 + exemestane in comparison to everolimus +\n      exemestane. Safety, tolerability and PK (in a subset of patients) will also be assessed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult women (\u2265 18 years of age) with metastatic or locally advanced breast cancer not\n             amenable to curative treatment by surgery or radiotherapy\n\n          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast\n             cancer\n\n          -  A representative tumor specimen must be available for molecular testing.  An archival\n             tumor sample may be submitted; if one is not available, a newly obtained tumor\n             specimen must be submitted instead\n\n          -  Postmenopausal women. Postmenopausal status is defined either by:\n\n          -  Age \u2265 18 with prior bilateral oophorectomy\n\n          -  Age \u2265 60 years\n\n          -  Age <60 years with amenorrhea for at least 12 months and both follicle-stimulating\n             hormone (FSH) and estradiol levels are in postmenopausal range (according to the\n             local laboratory)\n\n          -  Recurrence while on, or within 12 months of end of adjuvant treatment with letrozole\n             or anastrozole, or\n\n          -  Progression while on, or within one month of end of letrozole or anastrozole\n             treatment for locally advanced or metastatic breast cancer.\n\n          -  Patients must have:\n\n               -  Measurable disease*: At least one lesion that can be accurately measured in at\n                  least one dimension \u2265 20 mm with conventional imaging techniques or \u2265 10 mm with\n                  spiral CT or MRI or\n\n               -  Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable\n                  disease as defined above.\n\n          -  ECOG Performance Status 0-1.\n\n          -  Fasting serum cholesterol \u2264 300 mg/dl or 7.75 mmol/L and fasting triglycerides \u2264 2.5\n             \u00d7 ULN. In case one or both of these thresholds are exceeded, the patient can only be\n             included after initiation of statin therapy and when the above mentioned values have\n             been achieved.\n\n               -  Exception for Phase Ib patients: measurable disease is not required\n\n        Exclusion Criteria:\n\n          -  Her2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ\n             hybridization positive).\n\n          -  Patients who received more than one chemotherapy line for advanced breast cancer.\n\n          -  Previous treatment with CDK4/6 inhibitors, exemestane or mTOR inhibitors*.\n\n          -  History of active or symptomatic brain or other CNS metastases.\n\n          -  Impaired cardiac function or clinically significant cardiac diseases, including any\n             of the following:\n\n          -  Left ventricular ejection fraction (LVEF) < 45% or less than the institution lower\n             limit of normal as determined by multiple gated acquisition scan (MUGA) or\n             echocardiogram (ECHO)\n\n          -  Congenital long QT syndrome or family history of unexpected sudden cardiac death\n\n          -  QT corrected with Fredericia's (QTcF) >470 ms for females on screening ECG\n\n          -  Any other clinically significant heart disease such as angina pectoris, resting\n             bradycardia, left bundle branch block, ventricular tachyarrhythmia, unstable atrial\n             fibrillation, Right bundle branch block with left anterior hemiblock (bifascicular\n             block), acute myocardial infarction or any heart disease that requires the use of a\n             cardiac pacemaker or implantable cardioverter defibrillator \u2264 3 months prior to\n             starting study drug.\n\n          -  Patients who are currently receiving treatment with agents that are known to cause\n             QTc prolongation in humans.\n\n          -  Patients who are currently receiving treatment (within five days prior to\n             randomization) with agents that are metabolized predominantly through CYP3A4 and that\n             have a narrow therapeutic window.  Agents that are known strong inducers or\n             inhibitors CYP3A4 are prohibited (Refer to Appendix 4) * Exceptions for Phase Ib\n             patients:\n\n               1. Patients who received more than two prior lines of chemotherapy are eligible\n\n               2. Patients who received CDK4/6 inhibitors, exemestane or mTOR inhibitors are\n                  eligible"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "185", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857193", 
            "org_study_id": "CLEE011X2106"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "L-R-E arm", 
                    "L-E arm"
                ], 
                "description": "LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.", 
                "intervention_name": "LEE011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "L-R-E arm", 
                    "L-E arm", 
                    "R-E arm"
                ], 
                "description": "Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.", 
                "intervention_name": "Exemestane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "L-R-E arm", 
                    "R-E arm"
                ], 
                "description": "Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Exemestane", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Open label; dose escalation; ER+; LEE011; CDK4/6; everolimus; advanced breast cancer; mTor; HR+; Her2-", 
        "lastchanged_date": "March 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "anickel@hogonc.com", 
                    "last_name": "Amanda Nickel", 
                    "phone": "+1 479 872 8130"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "Highlands Oncology Group Dept of Highlands Oncology Grp"
                }, 
                "investigator": {
                    "last_name": "Joseph Thaddeus Beck", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clwitkowski@uams.edu", 
                    "last_name": "Cindy Witkowski", 
                    "phone": "501-686-8503"
                }, 
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72205"
                    }, 
                    "name": "University of Arkansas/ Arkansas Cancer Research Center Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Laura Hutchins", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kmkelly@mednet.ucla.edu", 
                    "last_name": "Kim Kelly", 
                    "phone": "+1 310 582 6324"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles UCLA SC"
                }, 
                "investigator": {
                    "last_name": "Sara Alsterlind Hurvitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kwill@azpoh.com", 
                    "last_name": "Kristina Will", 
                    "phone": "480-860-5000"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ"
                }, 
                "investigator": {
                    "last_name": "Giraldo Kato", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "matthew.diemer@ucdenver.edu", 
                    "last_name": "Matthew Diemer", 
                    "phone": "720-848-0664"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Jennifer Diamond", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dianec@flcancercare.com", 
                    "last_name": "Diane Chambers", 
                    "phone": "954-582-1850"
                }, 
                "facility": {
                    "address": {
                        "city": "Davie", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33328"
                    }, 
                    "name": "Florida Cancer Research Institute Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Tan-Chiu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kim.t.nguyen@emory.edu", 
                    "last_name": "Kim Nguyen", 
                    "phone": "404-778-4824"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University School of Medicine/Winship Cancer Institute Emory"
                }, 
                "investigator": {
                    "last_name": "Ruth M. O'Regan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mundda@oncmed.net", 
                    "last_name": "Milenna Undda", 
                    "phone": "847-410-0660"
                }, 
                "facility": {
                    "address": {
                        "city": "Park Ridge", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60068-0736"
                    }, 
                    "name": "Oncology Specialists, SC Dept.of Oncology Specialists"
                }, 
                "investigator": {
                    "last_name": "Sigrun Hallmeyer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lbisryu@horizonbioadvance.com", 
                    "last_name": "Larry Bisiryu"
                }, 
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47905"
                    }, 
                    "name": "Horizon Oncology Center Horizon Onc"
                }, 
                "investigator": {
                    "last_name": "Wael Harb", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "tmazac@partners.org", 
                    "last_name": "Taylor T Mazac", 
                    "phone": "617-643-2208"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Aditya Bardia", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "iversb@karmanos.org", 
                    "last_name": "Gail the Newth", 
                    "phone": "+1 313 576 8096"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University/Karmanos Cancer Institute Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Muaiad Kittaneh", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oneiilg@mskcc.org", 
                    "last_name": "Gerry O'Neill", 
                    "phone": "646-888-5341"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Oncology Dept."
                }, 
                "investigator": {
                    "last_name": "Shanu N. Modi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mk3007@columbia.edu", 
                    "last_name": "Mary Ann Kiernan", 
                    "phone": "212-304-5579"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center- New York Presbyterian Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Kevin Kalinsky", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "NCOncologyIDS@unch.unc.edu", 
                    "last_name": "Chirstine Tomari", 
                    "phone": "919-966-4432"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "University of North Carolina UNC 2"
                }, 
                "investigator": {
                    "last_name": "Carey K. Anders", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "caitlin.spontelli@osumc.edu", 
                    "last_name": "Caitlin Spontelli", 
                    "phone": "614-293-6401"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State"
                }, 
                "investigator": {
                    "last_name": "Bhuvaneswari Ramaswamy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hansedan@ohsu.edu", 
                    "last_name": "Daniel Hansen", 
                    "phone": "503-418-9736"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University SC-5"
                }, 
                "investigator": {
                    "last_name": "Stephen Chui", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Diadra.thomas@utsouthwestern.edu", 
                    "last_name": "Diadria Thomas", 
                    "phone": "214-648-5107"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390-8527"
                    }, 
                    "name": "University of Texas Southwestern Medical Center Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Arthur Frankel", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "DIWesterhold@mdanderson.org", 
                    "last_name": "Daniela Westerhold", 
                    "phone": "713-792-2921"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Marianna Chavez-MacGregor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Bentleigh", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3165"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6005"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "Australia", 
                        "zip": "92024"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "zip": "2610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Herblain cedex", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60389"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24105"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "state": "BG", 
                        "zip": "24128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cona", 
                        "country": "Italy", 
                        "state": "FE", 
                        "zip": "44100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "Italy", 
                        "state": "VR", 
                        "zip": "37126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet de LLobregat", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08907"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Belgium", 
                "France", 
                "Germany", 
                "Hong Kong", 
                "Italy", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase Ib/II Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Her2- Locally Advanced or Metastatic Breast Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hong Kong: Department of Health", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "DLT is defined as treatment-related toxicity (classified according Common Toxicity Criteria for Adverse Events (CTCAE) Version 4) occurring during the first 28 treatment days and meeting specific protocol-predefined criteria. The information will be integrated in a Bayesian logistic regression model with overdose control to estimate the maximum tolerated dose (MTD).", 
                "measure": "Incidence of dose limiting toxicity (DLT)- Phase Ib", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1- Day 28 of Cycle 1 (28 day cycle)"
            }, 
            {
                "description": "PFS is defined as the date of randomization to the date of the first radiologically documented disease progression (PD) or death due to any cause per local investigator assessment as per RECIST.", 
                "measure": "Progression Free Survival (PFS)- Phase II", 
                "safety_issue": "No", 
                "time_frame": "Approximately 26 months after FPFV"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857193"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Incidence of adverse events (based on CTCAE Version 4) summarized by system organ class and/or preferred term, severity and relation to study treatment.", 
                "measure": "Incidence of adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Every cycle (1 cycle = 28 days) until study evlauation completion visit"
            }, 
            {
                "description": "based on CTCAE Version 4- summarized by system organ class and/or preferred term, severity and relation to study treatment.", 
                "measure": "Incidence of serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "every cycle (1cycle = 28 days) until study evaluation completion"
            }, 
            {
                "description": "Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).", 
                "measure": "Plasma concentration-time profiles - Phase Ib/II", 
                "safety_issue": "No", 
                "time_frame": "6 cycles of treatment (28-day cycles)"
            }, 
            {
                "description": "ORR is defined as the proportion of patients with a best overall response of complete response or partial response.", 
                "measure": "Overall Response Rate (ORR)- Phase Ib and Phase II", 
                "safety_issue": "No", 
                "time_frame": "Approximately 26 months after FPFV"
            }, 
            {
                "description": "DOR is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.", 
                "measure": "Duration Of Response (DOR) - Phase Ib, Phase II", 
                "safety_issue": "No", 
                "time_frame": "Approximately 26 months after FPFV"
            }, 
            {
                "description": "OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.", 
                "measure": "Overall Survival (OS) - Phase II", 
                "safety_issue": "No", 
                "time_frame": "Approximately 26 months after FPFV"
            }, 
            {
                "description": "Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).", 
                "measure": "Plasma concentration-time profiles: AUCtau - Phase Ib/II", 
                "safety_issue": "No", 
                "time_frame": "6 Cycles of treatment (28 day cycles)"
            }, 
            {
                "description": "Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).", 
                "measure": "Plasma concentration-time profiles - Cmin Phase Ib/II", 
                "safety_issue": "No", 
                "time_frame": "6 Cycles of treatment (28 day cycles)"
            }, 
            {
                "description": "Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).", 
                "measure": "Plasma concentration-time profiles - Cmax Phase Ib/II", 
                "safety_issue": "No", 
                "time_frame": "6 Cycles of treatment (28 day cycles)"
            }, 
            {
                "description": "Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).", 
                "measure": "Plasma concentration-time profiles - Tmax Phase Ib/II", 
                "safety_issue": "No", 
                "time_frame": "6 Cycles of treatment (28 day cycles)"
            }, 
            {
                "description": "Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).", 
                "measure": "Plasma concentration-time profiles - Racc Phase Ib/II", 
                "safety_issue": "No", 
                "time_frame": "6 Cycles of treatment (28 day cycles)"
            }, 
            {
                "description": "DCR is the proportion of patients with a best overall response of CR or PR or SD.", 
                "measure": "Disease Control Rate (DCR) - Phase Ib, Phase II", 
                "safety_issue": "No", 
                "time_frame": "Approximately 26 months after FPFV"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}